9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 55

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Overall Survival (OS),  Number of participants with treatment-related adverse events as assessed by CTCAE v4.03,  Progression-Free Survival (PFS), Time to Progression (TTP) on Durvalumab

Interventions: Concurrent Durvalumab, Maintenance Durvalumab

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: August 2020

Completion Date: December 2020

Last  Posted Date: June 19, 2019

Location: University San Diego Moores Cancer Center, La Jolla, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT02899195

Was this article helpful?
Dislike 0